Jeff Bhatt
杰夫·巴特
MD
Executive Vice President & Chief Medical Officer, Moderna, Inc.Moderna公司执行副总裁兼首席医疗官
👥Biography 个人简介
Jeff Bhatt is Executive Vice President and Chief Medical Officer of Moderna, overseeing the clinical development of mRNA-4157/V940 (individualized neoantigen cancer vaccine) across pivotal phase 3 trials in melanoma, NSCLC, and bladder cancer. He leads Moderna's oncology clinical strategy, including biomarker identification and regulatory interactions for the cancer vaccine program.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Phase 3 Clinical Program for mRNA-4157/V940 in Melanoma and NSCLC
Designed and is overseeing the KEYNOTE-942 phase 3 expansion and INTerpath-009 NSCLC trial of mRNA-4157/V940 + pembrolizumab, advancing the individualized neoantigen cancer vaccine toward potential regulatory approval.
Biomarker Strategy for Personalized mRNA Cancer Vaccines
Led development of tumor mutational burden and neoantigen load biomarker frameworks to identify patients most likely to benefit from mRNA-4157/V940, supporting regulatory submissions and precision medicine positioning.
Expansion of mRNA Oncology Pipeline
Advanced Moderna's broader mRNA oncology portfolio including KRAS-targeted vaccines (mRNA-5671), intratumoral IL-2 (mRNA-2416), and combination immuno-oncology strategies beyond the individualized neoantigen approach.
Representative Works 代表性著作
mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab alone for resected high-risk melanoma (KEYNOTE-942): a randomised, phase 2b study
The Lancet (2023)
Key phase 2b trial demonstrating mRNA-4157/V940 + pembrolizumab reduced recurrence/death by 44% versus pembrolizumab alone in high-risk resected melanoma, supporting phase 3 advancement.
Safety and immunogenicity of individualized neoantigen therapy mRNA-4157 (V940) in combination with pembrolizumab in unresectable or metastatic solid tumors
Journal for ImmunoTherapy of Cancer (2023)
Demonstrates mRNA-4157's acceptable safety profile and ability to induce neoantigen-specific T cell responses across multiple solid tumor types, supporting broad oncology application.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
关注 杰夫·巴特 的研究动态
Follow Jeff Bhatt's research updates
留下邮箱，当我们发布与 Jeff Bhatt（Moderna, Inc.）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment